These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 7805856)
1. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. Borrel MN; Fiallo M; Priebe W; Garnier-Suillerot A FEBS Lett; 1994 Dec; 356(2-3):287-99. PubMed ID: 7805856 [TBL] [Abstract][Full Text] [Related]
2. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942 [TBL] [Abstract][Full Text] [Related]
3. Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox? Hu X; Yang H; Pan QR; Zheng S Chemotherapy; 1995; 41(4):296-305. PubMed ID: 7555211 [TBL] [Abstract][Full Text] [Related]
4. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811 [TBL] [Abstract][Full Text] [Related]
5. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Wielinga PR; Westerhoff HV; Lankelma J Eur J Biochem; 2000 Feb; 267(3):649-57. PubMed ID: 10651800 [TBL] [Abstract][Full Text] [Related]
6. Effects of xanthine derivatives on the influx and efflux of doxorubicin in P388 and DOX-resistant P388 leukemia cells. Sadzuka Y; Egawa Y; Sawanishi H; Miyamoto K; Sonobe T Toxicol Lett; 2002 Sep; 135(1-2):137-44. PubMed ID: 12243872 [TBL] [Abstract][Full Text] [Related]
8. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. Marbeuf-Gueye C; Ettori D; Priebe W; Kozlowski H; Garnier-Suillerot A Biochim Biophys Acta; 1999 Jul; 1450(3):374-84. PubMed ID: 10395948 [TBL] [Abstract][Full Text] [Related]
9. Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells. Tkaczyk-Gobis K; Tarasiuk J; Seksek O; Stefanska B; Borowski E; Garnier-Suillerot A Eur J Pharmacol; 2001 Feb; 413(2-3):131-41. PubMed ID: 11226386 [TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance protein functionality: no effect of intracellular or extracellular pH changes. Marbeuf-Gueye C; Priebe W; Garnier-Suillerot A Biochem Pharmacol; 2000 Nov; 60(10):1485-9. PubMed ID: 11020450 [TBL] [Abstract][Full Text] [Related]
11. Study of P-glycoprotein functionality in living resistant K562 cells after photolabeling with a verapamil analogue. Mankhetkorn S; Teodori E; Scapecchi S; Garnier-Suillerot A Biochem Pharmacol; 1996 Jul; 52(2):213-7. PubMed ID: 8694845 [TBL] [Abstract][Full Text] [Related]
12. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255 [TBL] [Abstract][Full Text] [Related]
13. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Mülder HS; Dekker H; Pinedo HM; Lankelma J Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681 [TBL] [Abstract][Full Text] [Related]
14. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Shiraki N; Hamada A; Ohmura T; Tokunaga J; Oyama N; Nakano M Biol Pharm Bull; 2001 May; 24(5):555-7. PubMed ID: 11379779 [TBL] [Abstract][Full Text] [Related]
15. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. Solary E; Ling YH; Perez-Soler R; Priebe W; Pommier Y Int J Cancer; 1994 Jul; 58(1):85-94. PubMed ID: 8014019 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Bennis S; Ichas F; Robert J Int J Cancer; 1995 Jul; 62(3):283-90. PubMed ID: 7628869 [TBL] [Abstract][Full Text] [Related]
17. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. Pereira E; Borrel MN; Fiallo M; Garnier-Suillerot A Biochim Biophys Acta; 1994 Jan; 1225(2):209-16. PubMed ID: 7904185 [TBL] [Abstract][Full Text] [Related]
18. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators. Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123 [TBL] [Abstract][Full Text] [Related]
19. Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100). Sognier MA; Zhang Y; Eberle RL; Sweet KM; Altenberg GA; Belli JA Biochem Pharmacol; 1994 Jul; 48(2):391-401. PubMed ID: 7914406 [TBL] [Abstract][Full Text] [Related]
20. Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin. Szwed M; Kania KD; Jozwiak Z Cell Oncol (Dordr); 2014 Dec; 37(6):421-8. PubMed ID: 25410120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]